Progress of radiotherapy for hilar cholangiocarcinoma

Abstract

Guo Jianyang, Liu Xia, Liao Rui, Du Chengyou. Progress of radiotherapy for hilar cholangiocarcinoma[J]. Journal of International Oncology, 2014, 41(5): 350-353.

［1］ Shi Z, Yang MZ, He QL, et a1. Addition of hepatectomy decreases liver reeurrenee and leads to long survival in hilar cholangiocareinoma［J］. World J Gastroenterol, 2009, 15(15):1892-1896. ［2］ Isayama H, Tsujino T, Nakai Y, et al. Clinical benefit of radiation therapy and metallic stenting for unresectable hilar cholangiocarcinoma［J］. World J Gastroenterol, 2012, 18(19):2364-2370. ［3］ Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma［J］. An Surg Oncol, 2011, 18(3):651-658. ［4］ Kim JY, Kang DH, Kim HW, et al. Usefulness of slimmer and opencelldesign stents for endoscopic bilateral stenting and endoscopic revision in patients with hilar cholangiocarcinoma (with video)［J］. Gastrointest Endosc, 2009, 70(6):1109-1115. ［5］ Minn AY, Koong AC, Chang DT. Stereotactic body radiation therapy for gastrointestinal malignancies［J］. Front Radiat Ther Oncol, 2011, 43:412-427. ［6］ Momm F, Schubert E, Henne K, et al. Stereotactic fractionated radiotherapy for Klatskin tumours［J］. Radiother Oncol, 2010, 95(1):99-102. ［7］ Polistina FA, Guglielmi R, Baiocchi C, et al. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, nonmetastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience［J］. Radiother Oncol, 2011, 99(2):120-123. ［8］ Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliarytract cancers and correlation of changes in 18fluorodeoxyglucose PET with clinical outcome: a phase 2 study［J］.Lancet Oncol, 2010, 11(1):48-54. ［9］ Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma［J］. An Surg, 2009, 250(6):950-956. ［10］ Patel T. Cholangiocarcinomacontroversies and challenges［J］. Nat Rev Gastroenterol Hepatol, 2011, 8(4):189-200. ［11］ Valero V 3rd, Cosgrove D, Herman JM, et al. Management of perihilar cholangiocarcinoma in the era of multimodal therapy［J］. Expert Rev Gastroenterol Hepatol, 2012, 6(4):481-495. ［12］ Murakami Y, Uemura K, Sudo T, et al. Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies［J］. J Gastrointest Surg, 2013, 17(8):1429-1439. ［13］ Salgia RJ, Singal AG, Fu S, et al. Improved posttransplant survival in the United States for patients with cholangiocarcinoma after 2000［J］. Dig Dis Sci, 2013, 16. ［14］ Darwish Murad S, Kim WR, Harnois DM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers［J］. Gastroenterology, 2012, 143(1):88-98. ［15］ Darwish Murad S, Heimbach JK, Gores GJ, et al. Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation［J］. Liver Transpl, 2013, 19(5):521-528. ［16］ Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment［J］. Hepatology, 2008, 48(1):308-321. ［17］ Hong JC, Petrowsky H, Kaldas FM, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma［J］. J Am Coll Surg, 2011, 212(4):514-520. ［18］ Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24year experience in a single center［J］. Arch Surg, 2011, 146(6):683-689. ［19］ Zamboglou C, Messmer MB, Becker G, et al. Stereotactic radiotherapy in the liver hilum. Basis for future studies［J］. Strahlenther Onkol, 2012, 188(1):35-41.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[11]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[12]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[13]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[14]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[15]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.

Progress of radiotherapy for hilar cholangiocarcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments